The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024
That said, most users cycle it simply because fat loss goals are achieved within 3-4 months, or they want to assess baseline after treatment
This allows there to be a lot more room within the central canal, decompressing the spinal cord and vascular structures
However, the limit to its reuse depends on several factors
Citation: He, D., Hu, H., Cai, X., Xue, W., Shen, W., & Han, J
You are building a regenerative environment